Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin. - Wikidata - awgldk - TriplyDB

Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin.

Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin.

http://www.wikidata.org/entity/Q37095692

about

Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India Safety considerations in drug treatment of depression in HIV-positive patients: an updated review.In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review.

P2860

Q24609011-82DCD6EE-BCA3-4570-9749-F64C46B3846C Q35065867-51126A99-889E-4306-99D7-E58CB77B6657 Q35102702-F6546B84-7F6C-416D-B5C2-71E9E334EC35 Q35132410-8ADB9942-391F-453E-A268-83BB5BC0B2C4 Q37115738-3BDB94A7-8FFB-48A5-BCA4-66ECFD3221F7 Q37900614-8B305062-ECEC-4A2A-90AF-53E1DA1E161E Q39773047-1DB8B16F-6297-43C3-BA4C-D4721A94EA0A Q52330065-B898A386-6EF2-4669-9B4E-D90DEC92D4AA

P2860

Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin.

http://www.wikidata.org/entity/Q37095692

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 February 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Are literature references suff ...... udy of efavirenz and rifampin.

@en

Are literature references suff ...... udy of efavirenz and rifampin.

@nl

type

label

Are literature references suff ...... udy of efavirenz and rifampin.

@en

Are literature references suff ...... udy of efavirenz and rifampin.

@nl

prefLabel

Are literature references suff ...... udy of efavirenz and rifampin.

@en

Are literature references suff ...... udy of efavirenz and rifampin.

@nl

P1433

Q37095692-E5568A4A-EA2E-4C7A-9B4E-C7B70DCB724D

P1476

Q37095692-2FC3BE4B-5A48-4D0B-9943-EEC4EBD218BB

P2093

Q37095692-0DEB85B8-1025-435C-9178-0D3A1E05E776

Q37095692-6433A54E-7D49-4B70-973D-317D2BF41ADE

Q37095692-DFDE9BAB-26D0-4E30-83BB-AC8D82EBB232

Q37095692-E69805A0-E714-4213-9BB5-FC7B65829F72

Q37095692-F99F291B-722A-4821-BACD-A33B5C69C654

P2860

Q37095692-16BFC34A-A945-449C-85A7-CA31686438D4

Q37095692-2173475A-C7AA-4800-B3FD-B6F55939153C

Q37095692-3A80DF8A-F97C-4553-8638-C94240E0319E

Q37095692-4B9EDE54-4412-4955-BD1B-053E63A43AF3

Q37095692-58AB96CD-C5B7-49AA-AF9A-BA92CE46837A

Q37095692-75B8FF1C-3B8D-4AF4-A0FD-499E23F4C73B

Q37095692-85243998-EBA2-4285-AFD2-73BF8592C999

Q37095692-8D3D67EF-694B-41CE-A588-2770420467E9

Q37095692-91594CFD-D0A4-48E7-80D8-D5D4E0C65AC5

Q37095692-93CEA228-6FB1-452F-B9AE-48A48BF932EB

P304

Q37095692-CC075951-E71D-4AFD-83EF-0040FDBE7CF6

P31

Q37095692-64F213E2-2261-4319-B7D8-45BB0EA2D8B1

P356

Q37095692-05E52849-5022-48AB-8414-68D3970FA6A8

P433

Q37095692-EC7ACE4A-5B5F-4A22-98A1-F108BCA83934

P478

Q37095692-0D2D6EE4-66A4-43C5-AFDF-0283A6BD7020

P577

Q37095692-6F96967F-5922-4A29-82F6-CF0734B373BB

P698

Q37095692-CA5CC4DC-2B51-4FB0-BBA3-33FD795B67CB

P356

0091270008315308

P1433

The Journal of Clinical Pharmacology

P1476

Are literature references suff ...... udy of efavirenz and rifampin.

@en

P2093

Jennifer L DiGiacinto

http://www.w3.org/2001/XMLSchema#string

Kellie S Reynolds

http://www.w3.org/2001/XMLSchema#string

Kimberly A Struble

http://www.w3.org/2001/XMLSchema#string

Kirk M Chan-Tack

http://www.w3.org/2001/XMLSchema#string

Sarah M Robertson

http://www.w3.org/2001/XMLSchema#string

P2860

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin.

Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all.

Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations.

P304

518-523

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270008315308

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18303126

http://www.w3.org/2001/XMLSchema#string